Corium International Company Profile (NASDAQ:CORI)

About Corium International (NASDAQ:CORI)

Corium International logoCorium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CORI
  • CUSIP: N/A
  • Web:
  • Market Cap: $207.84 million
  • Outstanding Shares: 29,232,000
Average Prices:
  • 50 Day Moving Avg: $5.17
  • 200 Day Moving Avg: $4.40
  • 52 Week Range: $2.67 - $8.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.23
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $32.84 million
  • Price / Sales: 6.33
  • Book Value: $0.07 per share
  • Price / Book: 101.57
  • EBIDTA: ($28,180,000.00)
  • Net Margins: -116.26%
  • Return on Equity: -359.24%
  • Return on Assets: -50.22%
  • Debt-to-Equity Ratio: 17.88%
  • Current Ratio: 6.06%
  • Quick Ratio: 5.75%
  • Average Volume: 156,898 shs.
  • Beta: 1.07
  • Short Ratio: 3.26

Frequently Asked Questions for Corium International (NASDAQ:CORI)

What is Corium International's stock symbol?

Corium International trades on the NASDAQ under the ticker symbol "CORI."

How were Corium International's earnings last quarter?

Corium International Inc (NASDAQ:CORI) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.05. The company had revenue of $7.35 million for the quarter, compared to analyst estimates of $6.05 million. Corium International had a negative net margin of 116.26% and a negative return on equity of 359.24%. View Corium International's Earnings History.

Where is Corium International's stock going? Where will Corium International's stock price be in 2017?

5 brokerages have issued twelve-month target prices for Corium International's stock. Their predictions range from $8.00 to $16.00. On average, they expect Corium International's stock price to reach $11.80 in the next twelve months. View Analyst Ratings for Corium International.

What are analysts saying about Corium International stock?

Here are some recent quotes from research analysts about Corium International stock:

  • 1. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (4/21/2017)
  • 2. Jefferies Group LLC analysts commented, "CORI posted a slightly narrower than expected loss (-$10.4M vs -$11.2M JEF). Key pipeline product donepezil TD finished the 2nd of three stages of the pilot study and remains on track to start the pivotal Ph 3 study in 2H17. Partners P&G and AGRX continue to support the topline but a new partnership remains key for FY17 in order for mgt to remain credible and generate much needed non-dilutive financing." (2/15/2017)
  • 3. Needham & Company LLC analysts commented, "CORI reported FY1Q17 financials and provided a development update for its Alzheimer's disease transdermal patch programs. The second treatment period of the ongoing pilot BE study for the donepezil patch recently completed and the first interim results are expected in March. The upcoming interim look could provide the initial derisking for the Corplex CNS patch program. CORI recently completed a $20MM equity raise that extends the cash runway into late-2017/ early-2018. We maintain our Buy rating and adjust our $PT to $10 (from $12) to reflect the new higher share count and expected volatility in revenues from partnered products." (2/14/2017)
  • 4. FBR & Co analysts commented, "Corium reported below-consensus revenue and EPS after the market close on November 21. While EPS and revenues were disappointing in the quarter, we believe that investors should continue to focus on the company’s impressive CNS patch pipeline. Corium has received favorable written feedback from the FDA regarding its development of Corplex donepezil and Corplex memantine. The FDA has indicated that if Corium can demonstrate bioequivalence between its products and oral Aricept (donepezil) and oral Namenda XR (memantine) in bioequivalence (BE) studies, then it could submit a 505(b)(2) NDA without conducting additional clinical efficacy trials. We believe meaningful catalysts are ahead in 2017. Patient dosing started in September for a pilot study for Corplex donepezil in preparation for the pivotal BE trial in 2H17." (11/22/2016)

Who are some of Corium International's key competitors?

Who are Corium International's key executives?

Corium International's management team includes the folowing people:

  • David L. Greenwood, Chairman of the Board
  • Peter D. Staple, President, Chief Executive Officer, Director
  • Robert S. Breuil, Chief Financial Officer
  • Parminder Singh Ph.D., Chief Technology Officer, Vice President - Research & Development
  • Joseph J. Sarret M.D. J.D., Chief Business Officer
  • Robert W. Thomas, Lead Independent Director
  • Eric H. Bjerkholt, Independent Director
  • Bhaskar Michael Chaudhuri Ph.D., Independent Director
  • Ronald W. Eastman, Independent Director
  • Phyllis I. Gardner M.D., Independent Director

Who owns Corium International stock?

Corium International's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BROADFIN CAPITAL, LLC (12.74%), PERCEPTIVE ADVISORS LLC (13.16%), Broadfin Capital LLC (9.54%), Perceptive Advisors LLC (9.08%), AWM Investment Company Inc. (8.39%) and Royce & Associates LP (1.88%). Company insiders that own Corium International stock include David Greenwood, Eric Bjerkholt and Perceptive Advisors Llc. View Institutional Ownership Trends for Corium International.

Who sold Corium International stock? Who is selling Corium International stock?

Corium International's stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC. View Insider Buying and Selling for Corium International.

Who bought Corium International stock? Who is buying Corium International stock?

Corium International's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, AWM Investment Company Inc., Broadfin Capital LLC, Royce & Associates LP, Vanguard Group Inc., Bank of New York Mellon Corp and Geode Capital Management LLC. Company insiders that have bought Corium International stock in the last two years include David Greenwood, Eric Bjerkholt and Perceptive Advisors Llc. View Insider Buying and Selling for Corium International.

How do I buy Corium International stock?

Shares of Corium International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corium International's stock price today?

One share of Corium International stock can currently be purchased for approximately $7.11.

MarketBeat Community Rating for Corium International (NASDAQ CORI)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  246
MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Corium International (NASDAQ:CORI) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.80 (65.96% upside)

Analysts' Ratings History for Corium International (NASDAQ:CORI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017Cantor FitzgeraldReiterated RatingOverweight$10.00 -> $12.00HighView Rating Details
4/20/2017Jefferies Group LLCSet Price TargetBuy$8.00LowView Rating Details
4/18/2017FBR & CoReiterated RatingOutperform -> Outperform$12.00 -> $13.00LowView Rating Details
4/14/2017Needham & Company LLCReiterated RatingBuy$10.00N/AView Rating Details
1/4/2017Leerink SwannReiterated RatingBuyN/AView Rating Details
5/3/2016WBB SecuritiesUpgradeHold -> Speculative Buy$11.00N/AView Rating Details
6/9/2015GuggenheimInitiated CoverageBuy$18.00N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Corium International (NASDAQ:CORI)
Earnings by Quarter for Corium International (NASDAQ:CORI)
Earnings History by Quarter for Corium International (NASDAQ CORI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q2 2017($0.37)($0.42)$6.05 million$7.35 millionViewN/AView Earnings Details
2/13/2017Q1 2017($0.42)($0.46)$8.07 million$7.00 millionViewN/AView Earnings Details
11/21/2016Q4 2016($0.39)($0.42)$9.08 million$7.92 millionViewN/AView Earnings Details
8/4/2016Q3($0.42)($0.34)$8.38 million$10.61 millionViewN/AView Earnings Details
5/10/2016Q2($0.37)($0.47)$8.64 million$6.96 millionViewListenView Earnings Details
2/8/2016Q1($0.35)($0.42)$8.93 million$7.54 millionViewN/AView Earnings Details
11/12/2015Q4($0.45)($0.42)$9.47 million$9.27 millionViewListenView Earnings Details
7/29/2015Q3($0.37)($0.33)$10.45 million$10.60 millionViewListenView Earnings Details
2/10/2015Q115($0.29)($0.37)$10.42 million$9.77 millionViewN/AView Earnings Details
11/17/2014Q4 2014($0.32)($0.51)$10.26 million$11.07 millionViewN/AView Earnings Details
8/12/2014Q3 2014($0.17)($0.28)$12.22 million$10.18 millionViewN/AView Earnings Details
5/13/2014Q2 2014($0.18)($0.24)$10.58 million$10.72 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Corium International (NASDAQ:CORI)
2017 EPS Consensus Estimate: ($1.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.50)($0.39)($0.43)
Q2 20173($0.44)($0.36)($0.39)
Q3 20173($0.41)($0.24)($0.34)
Q4 20173($0.45)($0.27)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for Corium International (NASDAQ:CORI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Corium International (NASDAQ:CORI)
Insider Ownership Percentage: 45.70%
Institutional Ownership Percentage: 67.75%
Insider Trades by Quarter for Corium International (NASDAQ:CORI)
Institutional Ownership by Quarter for Corium International (NASDAQ:CORI)
Insider Trades by Quarter for Corium International (NASDAQ:CORI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017Perceptive Advisors LlcMajor ShareholderBuy1,902,400$6.25$11,890,000.00View SEC Filing  
5/19/2016Eric BjerkholtDirectorBuy24,500$3.64$89,180.00View SEC Filing  
5/12/2016David GreenwoodDirectorBuy3,000$3.58$10,740.00View SEC Filing  
2/25/2015Peter D StapleCEOBuy3,600$6.99$25,164.00View SEC Filing  
11/24/2014Robert S BreuilCFOBuy4,600$5.38$24,748.00View SEC Filing  
11/21/2014Peter D StapleCEOBuy9,000$5.34$48,060.00View SEC Filing  
8/27/2014Peter D StapleCEOBuy2,578$6.10$15,725.80View SEC Filing  
5/30/2014Peter D StapleCEOBuy7,200$7.04$50,688.00View SEC Filing  
4/8/2014Woodlands Health Venture EssexMajor ShareholderBuy400,000$8.00$3,200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Corium International (NASDAQ:CORI)
Latest Headlines for Corium International (NASDAQ:CORI)
DateHeadline logoETFs with exposure to Corium International, Inc. : May 25, 2017 - May 25 at 5:59 PM logoCorium International Inc (CORI) Major Shareholder Purchases $11,890,000.00 in Stock - May 25 at 1:20 PM logoCorium Hopes Stock Offering Will Firm Its Footing In Pharma Partner Talks - May 25 at 12:16 PM logoCorium International, Inc. :CORI-US: Earnings Analysis: Q2, 2017 By the Numbers : May 24, 2017 - May 24 at 12:42 PM logoCorium International Inc (CORI) Receives Average Rating of "Buy" from Analysts - May 19 at 8:58 PM logoCan The Uptrend Continue for Corium International (CORI)? - May 18 at 11:04 AM logoCorium International, Inc. 2017 Q2 - Results - Earnings Call Slides - May 14 at 4:32 PM logoBRIEF-Corium reports positive preliminary results in Alzheimer’s clinical study - May 12 at 9:57 PM logoCorium International Inc (CORI) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS - May 12 at 1:42 PM logoCorium International Inc (CORI) Stock Rating Reaffirmed by Cantor Fitzgerald - May 12 at 11:40 AM logoEdited Transcript of CORI earnings conference call or presentation 11-May-17 12:30pm GMT - May 11 at 10:05 PM logoCorium Reports Positive Preliminary Results in Alzheimer’s Clinical Study - May 11 at 5:03 PM logoCorium reports 2Q loss - May 11 at 5:03 PM logoCorium to Report Preliminary Results from Corplex Donepezil Pilot Study and Second Quarter Fiscal 2017 Financial Results Before Market Open on Thursday, May 11, 2017 - May 9 at 4:26 PM logo Brokerages Anticipate Corium International Inc (CORI) Will Post Quarterly Sales of $6.05 Million - May 7 at 8:16 AM logoBRIEF-RTW Investments reports 5 pct passive stake in Corium International - May 5 at 9:41 PM logoZacks: Analysts Expect Corium International Inc (CORI) to Announce -$0.41 Earnings Per Share - May 5 at 12:18 PM logoCorium International Has A New Take On A Great Drug - May 2 at 4:32 PM logoCorium International (CORI) Receiving Positive News Coverage, Report Shows - May 2 at 3:20 PM logoBRIEF-Corium International says entered supply agreement with Procter & Gamble Manufacturing Co - May 1 at 8:26 AM logoCorium International (CORI) Receives Daily News Impact Score of 0.30 - April 27 at 7:26 PM logoCorium International Inc (CORI) Raised to "Buy" at Zacks Investment Research - April 27 at 7:18 AM logoCorium International Inc (CORI) Receives Consensus Rating of "Buy" from Brokerages - April 24 at 9:42 PM logoCorium International (CORI) Earns Daily Media Impact Score of 0.31 - April 24 at 5:35 PM logoCorium International Inc (CORI) Upgraded to "Buy" at Zacks Investment Research - April 21 at 9:44 PM logoCorium International Inc (CORI) Given a $8.00 Price Target by Jefferies Group LLC Analysts - April 21 at 4:23 PM logoCorium International (CORI) Getting Favorable News Coverage, Report Shows - April 21 at 2:16 PM logoQ2 2017 Earnings Estimate for Corium International Inc Issued By FBR & Co (CORI) - April 21 at 10:31 AM logoCorium International (CORI) Given News Sentiment Rating of 0.21 - April 18 at 3:48 PM logo$6.37 Million in Sales Expected for Corium International Inc (CORI) This Quarter - April 16 at 8:58 AM logoCorium International (CORI) Receives Media Impact Rating of 0.17 - April 15 at 4:00 PM logoCorium International's (CORI) Buy Rating Reiterated at Needham & Company LLC - April 14 at 9:17 PM logoCorium International Inc (CORI) Expected to Announce Earnings of -$0.39 Per Share - April 14 at 11:26 AM logoETFs with exposure to Corium International, Inc. : April 7, 2017 - April 7 at 4:24 PM logoCorium International (CORI) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 9:07 AM logoCorium International Inc (CORI) Short Interest Update - April 5 at 10:18 PM logoCorium International Inc (CORI) Given Average Rating of "Buy" by Analysts - March 29 at 12:52 PM logoCorium International's (CORI) Buy Rating Reaffirmed at Jefferies Group LLC - March 23 at 10:49 AM logoCorium to Participate in BioPharma Dealmakers Webcast on New Innovations in Drug Delivery Technology - March 22 at 4:33 PM logoCorium International Inc (CORI) Earns Buy Rating from FBR & Co - March 21 at 9:25 PM logoCorium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex™ Donepezil Patch - March 20 at 4:25 PM logoCorium International, Inc. :CORI-US: Earnings Analysis: Q1, 2017 By the Numbers : March 20, 2017 - March 20 at 4:25 PM logoCORIUM INTERNATIONAL, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - March 9 at 4:59 PM logoCORIUM INTERNATIONAL, INC. Financials - February 26 at 4:10 PM logoCORIUM INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report - February 14 at 5:14 PM logoEdited Transcript of CORI earnings conference call or presentation 13-Feb-17 10:00pm GMT - February 14 at 5:14 PM logoQ1 2017 Corium International Inc Earnings Release - After Market Close - February 13 at 5:06 PM logoCorium Reports First Quarter Fiscal 2017 Financial Results - February 13 at 5:06 PM logoCorium to Present at Upcoming Investor Conferences - February 7 at 5:33 PM logoCorium to Report First Quarter Fiscal Year 2017 Financial Results on Monday, February 13, 2017 - February 6 at 4:29 PM



Corium International (CORI) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff